As per DelveInsight Business Research LLP analysis, of all the Wet Age-related Macular Degeneration emerging therapies, the most anticipated product to get launched is Abicipar Pegol, a lead candidate of Allergan. Several other emerging #therapies such as GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, IBI 302 by Innovent Biologics（信达生物制药）and FYB201 by Bbioeq GmbH are also expected to shift the Wet Age-related macular degeneration landscape positively. For more details visit: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration-treatment-market/ #market #marketresearch #pharma #biotech #lifescience #medical #healthcare #maculardegeneration